Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Apatinib and POF in Advanced Gastric Cancer
NCT04174339Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04174339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174339.